RYBREVANT HYLAPRO
Live / Applied — Second extension granted (statement of use) (as of 11 Nov 2025)
What this means for you
Not registered yet, but its 12 Jun 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98597888
- Mark type
- Stylized text
- Filed
- 12 Jun 2024
- Published for opposition
- 15 Oct 2024
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 12 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Nov 2025 — SOU EXTENSION 2 GRANTED
- 11 Nov 2025 — SOU EXTENSION 2 FILED
- 11 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 23 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Apr 2025 — SOU EXTENSION 1 GRANTED
- 22 Apr 2025 — SOU EXTENSION 1 FILED
- 22 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 15 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Oct 2024 — PUBLISHED FOR OPPOSITION
- 25 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 Sept 2024 — ASSIGNED TO EXAMINER
- 12 Jun 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED